Home          View all 329 MoA classes  

      

Enter a class name or drug name above to search the database.

Programmed Death Receptor-1-directed Antibody Interactions [MoA] Mechanism of Action Drugs

NDC Number Brand Name Generic Name Labeler Dosage Form DEA Schedule Marketing Start Date
0003-3734 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2017-12-08
0003-3756 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2021-08-30
0003-3772 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2014-12-22
0003-3774 OPDIVO nivolumab E.R. Squibb & Sons, L.L.C. INJECTION 2014-12-22
0003-6120 OPDIVO QVANTIG nivolumab and hyaluronidase-nvhy E.R. Squibb & Sons, L.L.C. INJECTION, SOLUTION 2025-01-02
0003-7125 OPDUALAG nivolumab and relatlimab-rmbw E.R. Squibb & Sons, L.L.C. INJECTION 2022-03-18
0006-3026 KEYTRUDA pembrolizumab Merck Sharp & Dohme LLC INJECTION, SOLUTION 2015-01-15
0006-3083 KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfa-pmph Merck Sharp & Dohme LLC INJECTION, SOLUTION 2025-09-19
0006-5083 KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfa-pmph Merck Sharp & Dohme LLC INJECTION, SOLUTION 2025-09-19
0173-0898 Jemperli dostarlimab GlaxoSmithKline LLC INJECTION 2021-04-22
50242-917 TECENTRIQ atezolizumab Genentech, Inc. INJECTION, SOLUTION 2016-05-18
50242-918 TECENTRIQ atezolizumab Genentech, Inc. INJECTION, SOLUTION 2019-03-08
50242-933 Tecentriq Hybreza atezolizumab and hyaluronidase-tqjs Genentech, Inc. INJECTION 2024-09-12
50881-006 ZYNYZ retifanlimab-dlwr Incyte Corporation INJECTION 2023-03-22
70114-340 LOQTORZI toripalimab-tpzi Coherus BioSciences, Inc. INJECTION 2023-10-27
72579-121 TEVIMBRA tislelizumab-jsgr BeOne Medicines USA, Inc. INJECTION, SOLUTION, CONCENTRATE 2024-03-14

 Mechanism of Action Classification 

Loading full table content...